Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ionis Pharmaceuticals (NQ: IONS ) 42.39 -5.94 (-12.29%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ionis Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 Next > Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio January 08, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily 2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs January 04, 2024 A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... Via Benzinga Topics ETFs Where Ionis Pharmaceuticals Stands With Analysts November 17, 2023 Via Benzinga Analyst Expectations for Ionis Pharmaceuticals's Future October 23, 2023 Via Benzinga Analyst Expectations for Ionis Pharmaceuticals's Future September 27, 2023 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session January 02, 2024 Via Benzinga 3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies December 27, 2023 These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024. Via InvestorPlace Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential December 22, 2023 Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am Via Benzinga Exposures Product Safety New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment December 22, 2023 Friday, FDA approved AstraZeneca Via Benzinga Exposures Product Safety Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach December 19, 2023 Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,... Via Benzinga Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout. December 19, 2023 IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Reveals Intriguing Technical Aspects. Here's What You Need to Know. Via Chartmill Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies November 16, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent? November 10, 2023 Technical Setup: IONIS PHARMACEUTICALS INC Appears Poised for a Breakout. Via Chartmill Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat November 02, 2023 Via Benzinga Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? October 17, 2023 Via Benzinga Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day October 02, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges September 27, 2023 Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY Via Benzinga Why Ionis Pharmaceuticals Stock Popped Today September 26, 2023 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 September 29, 2023 Via Benzinga Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action September 26, 2023 Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents... Via Benzinga Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder September 26, 2023 IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. Via Investor's Business Daily Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Highlighted for Surprising Price Action September 26, 2023 Via Investor Brand Network The 7 Most Hated Stocks by Institutional Traders September 20, 2023 Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future. Via InvestorPlace Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope September 07, 2023 Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, Via Benzinga Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports August 07, 2023 Via Benzinga Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook July 31, 2023 Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 July 31, 2023 Via Benzinga Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday July 31, 2023 Keybanc cut the price target for Baxter International Inc. (NYSE: BAX) from $53 to $51. Keybanc analyst Matthew Mishan maintained an Overweight rating. Baxter International shares rose 1.2% to $47.58... Via Benzinga BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease July 17, 2023 The companies are working on treatments for a leading cause of heart failure. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.